What are the Considerations in Balancing Benefits and Risks in Iron Treatment?-Reference-Cited by-同舟云学术

What are the Considerations in Balancing Benefits and Risks in Iron Treatment?

Published:2016-09-27 Issue:1 Volume:30 Page:20-22
ISSN:0894-0959
Container-title:Seminars in Dialysis
language:en
Short-container-title:Semin Dial

Author:

Wish Jay B.¹

Affiliation:

1. Division of Nephrology; Indiana University Health; Indianapolis Indiana

Publisher

Wiley

Subject

Nephrology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/sdi.12552/fullpdf

Reference15 articles.

1. Clinical practice guidelines for anemia of chronic kidney failure;National Kidney Foundation Dialysis Outcomes Quality Initiative;Am J Kidney Dis,1997

2. Clinical practice guideline for anemia in chronic kidney disease;Kidney Disease Improving Global Outcomes;Kidney Int Supplements,2012

3. Blood loss during maintenance hemodialysis;Longnecker;Trans Am Soc Artif Intern Organs,1974

4. Dialyzer blood loss;Lindsay;Clin Nephrol,1973

5. Iron requirements in hemodialysis;Sargent;Blood Purif,2004

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ethnicity evaluation of ferric pyrophosphate citrate among Asian and Non-Asian populations: a population pharmacokinetics analysis;European Journal of Clinical Pharmacology;2022-06-17

2. Anemia Treatment After 30 Years of Erythropoietic Stimulating Agents: No Longer Business as Usual?;Advances in Chronic Kidney Disease;2019-07

3. Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents;Nephrology Dialysis Transplantation;2018-04-16

4. Ferric Carboxymaltose: A Review in Iron Deficiency;Drugs;2018-03

5. Positive Iron Balance in Chronic Kidney Disease: How Much is Too Much and How to Tell?;American Journal of Nephrology;2018